Tuberculosis preventive therapy for people living with HIV: A systematic review and network meta-analysis
Mercedes Yanes-Lane,
Edgar Ortiz-Brizuela,
Jonathon R Campbell,
Andrea Benedetti,
Gavin Churchyard,
Olivia Oxlade and
Dick Menzies
PLOS Medicine, 2021, vol. 18, issue 9, 1-23
Abstract:
Background: Tuberculosis (TB) preventive therapy (TPT) is an essential component of care for people living with HIV (PLHIV). We compared efficacy, safety, completion, and drug-resistant TB risk for currently recommended TPT regimens through a systematic review and network meta-analysis (NMA) of randomized trials. Methods and findings: We searched MEDLINE, Embase, and the Cochrane Library from inception through June 9, 2020 for randomized controlled trials (RCTs) comparing 2 or more TPT regimens (or placebo/no treatment) in PLHIV. Two independent reviewers evaluated eligibility, extracted data, and assessed the risk of bias. We grouped TPT strategies as follows: placebo/no treatment, 6 to 12 months of isoniazid, 24 to 72 months of isoniazid, and rifamycin-containing regimens. A frequentist NMA (using graph theory) was carried out for the outcomes of development of TB disease, all-cause mortality, and grade 3 or worse hepatotoxicity. For other outcomes, graphical descriptions or traditional pairwise meta-analyses were carried out as appropriate. The potential role of confounding variables for TB disease and all-cause mortality was assessed through stratified analyses. Conclusions: Rifamycin-containing regimens appear safer and at least as effective as isoniazid regimens in preventing TB and death and should be considered part of routine care in PLHIV. Knowledge gaps remain as to which specific rifamycin-containing regimen provides the optimal balance of efficacy, completion, and safety. Mercedes Yanes-Lane and co-workers report a systematic review and network meta-analysis of clinical trial evidence on tuberculosis preventive therapy options for people with HIV infection.Why was this study done?: What did the researchers do and find?: What do these findings mean?:
Date: 2021
References: View complete reference list from CitEc
Citations: View citations in EconPapers (1)
Downloads: (external link)
https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003738 (text/html)
https://journals.plos.org/plosmedicine/article/fil ... 03738&type=printable (application/pdf)
Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
HTML/Text
Persistent link: https://EconPapers.repec.org/RePEc:plo:pmed00:1003738
DOI: 10.1371/journal.pmed.1003738
Access Statistics for this article
More articles in PLOS Medicine from Public Library of Science
Bibliographic data for series maintained by plosmedicine ().